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Endofin, a novel BMP-SMAD 
regulator of the iron-regulatory 
hormone, hepcidin
Justin B. Goh1,2, Daniel F. Wallace1,2, Wanjin Hong3 & V. Nathan Subramaniam1,2
BMP-SMAD signalling plays a crucial role in numerous biological processes including embryonic 
development and iron homeostasis. Dysregulation of the iron-regulatory hormone hepcidin is 
associated with many clinical iron-related disorders. We hypothesised that molecules which mediate 
BMP-SMAD signalling play important roles in the regulation of iron homeostasis and variants in 
these proteins may be potential genetic modifiers of iron-related diseases. We examined the role of 
endofin, a SMAD anchor, and show that knockdown of endofin in liver cells inhibits basal and BMP-
induced hepcidin expression along with other BMP-regulated genes, ID1 and SMAD7. We show for 
the first time, the in situ interaction of endofin with SMAD proteins and significantly reduced SMAD 
phosphorylation with endofin knockdown, suggesting that endofin modulates hepcidin through BMP-
SMAD signalling. Characterisation of naturally occurring SNPs show that mutations in the conserved 
FYVE domain result in mislocalisation of endofin, potentially affecting downstream signalling and 
modulating hepcidin expression. In conclusion, we have identified a hitherto unrecognised link, 
endofin, between the BMP-SMAD signalling pathway, and the regulation of hepcidin expression and 
iron homeostasis. This study further defines the molecular network involved in iron regulation and 
provides potential targets for the treatment of iron-related disorders.
The transforming growth factor-β (TGFβ ) family is composed of 33 structurally related growth factors 
including TGFβ and bone morphogenetic proteins (BMPs) which regulate a wide variety of cellular 
responses such as proliferation, differentiation and apoptosis1–4. The TGFβ family members bind to two 
distinct serine/threonine kinase receptors on cellular membranes, termed type I and type II receptors5,6. 
Upon ligand binding, type II receptors phosphorylate type I receptors at the glycine-serine (GS) domain 
resulting in phosphorylation and activation of receptor-regulated small mothers against decapentaplegic 
(R-SMADs)7,8. TGFβ and activin signals activate the R-SMADs: SMAD2 and SMAD3, while BMP sig-
nals activate SMAD1, SMAD5, and SMAD89,10. R-SMADs subsequently form a heterocomplex with the 
common mediator SMAD, SMAD4, before translocating to the nucleus to activate the transcription of 
various target genes11.
SMAD anchors are recently identified adaptor molecules which facilitate interactions between TGFβ 
receptors and SMAD proteins, enhancing signal transduction and expression of target genes12,13. TGFβ 
signalling is mediated by the SMAD anchor for receptor activation (SARA) while signalling in the BMP 
pathway is mediated by the endosome-associated FYVE-domain protein (endofin)14. Endofin, encoded 
by the ZFYVE16 gene, contains a conserved double zinc finger, the FYVE (Fab-1, YGL023, Vps27, and 
EEA1) domain14,15. The FYVE domain is a cysteine-rich Zn2+ binding domain with a basic motif that binds 
to phosphatidylinositol-3-phosphate (PI3P), a lipid highly enriched in early endosomes16,17. Therefore, 
the FYVE domain is consequently responsible for localising endofin to endosomal vesicles which is 
important for its function in trafficking SMADs to internalised BMP receptors in early endosomes14. 
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Perturbing the FYVE-domain, as with the previously reported C753S mutation, mislocalises endofin and 
attenuates BMP signalling13,14.
Disruption of TGFβ superfamily signalling has been associated with cancer, cardiovascular, fibrotic 
and skeletal diseases18. BMP-SMAD signalling is also central to iron homeostasis through the regulation 
of hepcidin, a peptide hormone encoded by the HAMP gene, responsible for regulating serum iron 
levels. Most iron disorders are associated with a dysregulation of hepcidin. Iron overload resulting from 
hepcidin deficiency causes hyperabsorption of dietary iron and can lead to tissue and organ damage19. In 
contrast, excess hepcidin limits dietary iron absorption and macrophage iron recycling, restricting iron 
availability to erythrocyte precursors and eventually causing iron-restricted anaemia. As such, hepcidin 
regulation is tightly controlled at many levels. This includes BMPs which bind to trans-membrane BMP 
receptors, facilitated by hemojuvelin (HJV), a co-receptor that enhances BMP signalling to induce the 
transcription of HAMP, together with other BMP-regulated genes such as ID1 (inhibitor of DNA binding 
protein 1) and SMAD7 (SMAD family member 7)20–22.
We hypothesised that endofin plays an important role in the regulation of hepcidin as it has been 
shown to be important in BMP-SMAD signalling. In this study, we investigated the potential role of endo-
fin in hepcidin regulation in the BMP-SMAD pathway. In addition, we characterised naturally-occurring 
SNPs affecting the conserved FYVE domain of endofin to elucidate potential effects of endofin polymor-
phisms on BMP signalling and hepcidin regulation. Our finding further defines the molecular network 
involved in iron regulation, providing potential targets for the treatment of iron-related disorders and 
possibly BMP-associated disorders.
Results
Endofin knockdown down-regulates basal hepcidin expression. To determine the role of end-
ofin on hepcidin regulation, we first examined the effect of modulating endofin levels by treating the 
human hepatic cell line, HepG2/C3A, with either non-specific siRNA or endofin-specific siRNA. Cells 
were incubated with siRNAs from 24 hr to 96 hr. We observed that endofin expression, as measured by 
quantitative real time PCR (qPCR), was significantly decreased compared to controls (Fig. 1a). Endofin 
expression was significantly decreased at all time points, being at approximately 50% of control levels at 
24 hr (p = 0.006), with a maximum of 70% knockdown at 72 hr (p < 0.001). Endofin expression remained 
effectively decreased up to 96 hr post transfection.
Following endofin knockdown, we observed a significant decrease in basal HAMP expression in C3A 
cells across all time points (Fig.  1b). Similar to endofin, HAMP expression was maximally reduced at 
72 hr (p < 0.001), down to 10% of control levels and remained decreased at 96 hr (p < 0.001).
Analysis of BMP-regulated genes, ID1 and SMAD7, containing BMP responsive elements in their 
promoters, showed that basal levels were decreased following endofin knockdown, although the amount 
of decrease was less than that of HAMP and only statistically significant at the 72 hr (p < 0.001) and 96 hr 
time points (p < 0.001) (Fig. 1c,d).
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Figure 1. Endofin silencing is associated with reduced basal hepcidin expression. HepG2/C3A cells were 
transfected with either non-specific siRNA (si-NS, white bars) or endofin siRNA (si-Endofin, black bars) 
from 24 to 96 hr. The mRNA expression of (a) ZFYVE16 (Endofin), (b) HAMP, (c) ID1 and (d) SMAD7 
were measured by qPCR and normalised to the geometric means of the reference genes ACTB and HPRT. 
Data are representative of three independent biological experiments. Bars represent means ± standard errors 
of triplicates. P-values of endofin knockdown relative to si-NS controls were calculated using 2-way ANOVA; 
*indicates a p-value of < 0.05, **p < 0.01, ***p < 0.001.
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BMP6 induction of hepcidin is disrupted by endofin knockdown. We next analysed the ability 
of BMP6 to regulate hepcidin in the absence of endofin. C3A cells were incubated with control and 
endofin-specific siRNA for 72 hr and subsequently treated with BMP6. Increasing amounts of BMP6 
treatment at concentrations of 1, 10 or 100 ng/ml for 4 hr increased HAMP expression by approximately 
10-, 60- and 100-fold respectively. Endofin expression was significantly decreased in cells treated with 
endofin-specific siRNA, regardless of BMP6-treatments (p < 0.001) (Fig.  2a). Despite BMP6-induction 
of HAMP at all concentrations, we observed up to 90% decreased expression following endofin silencing 
(Fig. 2b). This decrease in HAMP expression following endofin knockdown was similar to that observed 
in untreated C3A cells, expressing at approximately 10% of non-specific siRNA control levels.
BMP-regulated genes ID1 and SMAD7 were also inhibited following endofin knockdown and BMP6 
treatment. Although, the magnitude of induction by BMP6 and inhibition following endofin knockdown 
was less than observed with HAMP expression (Fig. 2c,d).
Duolink Proximity Ligation Assay shows in situ interaction of SMAD1 with endofin but not 
SARA. To assess if endofin modulates hepcidin through the BMP-SMAD signalling pathway, we ana-
lysed SMAD1 interactions with endofin using a proximity ligation assay (PLA). PLA is a new technology 
which allows for in situ detection of protein-protein interactions. PLA utilises antibody recognition cou-
pled with PLA probes which generate a localised signal in a form of spots, revealing proteins which are 
in close proximity (< 40 nm). In this assay, we used as controls the SMAD anchor SARA and SMAD2/3, 
which are closely related signalling components of the TGFβ but not the BMP pathway. C3A cells were 
transfected with either myc-tagged endofin or myc-tagged SARA constructs for 48 hr before processing 
for PLA.
Through PLA, we observed endofin interaction with endogenous SMAD1 proteins, localised in cyto-
plasmic regions of the cell (Fig. 3). We found that endofin also interacted with SMAD2/3 although fewer 
signal spots were observed. We show that SARA interacts exclusively with SMAD2/3 and not SMAD1 
(Fig. 3). These interactions were only observed in transfected cells indicating the specificity of the assay. 
Cells incubated with single antibodies showed low or no signal and were used to assess background 
signal (Fig. 3).
SMAD1/5/8 phosphorylation is reduced with endofin knockdown. To determine if the reg-
ulation of hepcidin expression by endofin occurs through the BMP-SMAD signalling pathway, we 
analysed the phosphorylation of SMAD1/5/8 proteins following endofin knockdown. C3A cells were 
knocked-down for endofin and treated with BMP6 (10 ng/ml) for 4 hr. In addition to protein analysis, 
mRNA levels of HAMP, ID1 and SMAD7 were measured by qPCR to verify the downstream effects on 
BMP-regulated gene transcription.
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Figure 2. BMP-induced HAMP, ID1 and SMAD7 levels are decreased following endofin knockdown. 
C3A cells were transfected with either non-specific siRNA (si-NS, white bars) or endofin siRNA (si-Endofin, 
black bars) for 72 hr and treated with BMP6 at 1, 10 or 100 ng/ml for 4 hr. The mRNA expression of (a) 
ZFYVE16 (Endofin), (b) HAMP, (c) ID1 and (d) SMAD7 were measured by qPCR and normalised to the 
geometric means of the reference genes ACTB and HPRT. Data are representative of three independent 
biological experiments. Bars represent means ± standard errors of triplicates. P-values were calculated using 
2-way ANOVA; *indicates a p-value of < 0.05, **p < 0.01, ***p < 0.001.
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After a 72 hr treatment with endofin-specific siRNA, immunoblotting showed reduced endofin protein 
levels in both BMP6 treated and untreated C3A cells (Fig. 4a,b). We observed a significant increase in 
SMAD1/5/8 phosphorylation in cells treated with BMP6 (p < 0.001), as reported previously23. Knockdown 
of endofin resulted in significantly decreased SMAD1/5/8 phosphorylation compared to controls in both 
Figure 3. Proximity ligation assay shows that endofin but not SARA interacts with SMAD1. C3A 
cells were transfected with either myc-tagged endofin or myc-tagged SARA plasmids for 48 hr before 
processing for PLA with myc, SMAD1, and SMAD2/3 total antibodies. As a negative control, C3A cells 
were incubated with one antibody (top panel) and for a positive control, we used endogenous TfR1 which 
forms homodimers. The remaining panels show cells incubated with two antibodies to assess SMAD anchor 
and SMAD protein interaction. Cells were incubated with anti-mouse secondary antibodies after the PLA 
experiment to identify transfected cells (left panel). The middle panel shows PLA assessment of SMAD 
anchor and SMAD interaction and the right panel shows a merged immunofluorescence (IF) and PLA 
image. Nuclei were stained with DAPI as shown in the middle and right panel. Data are representative of 
three independent biological experiments. Scale bar represents 20 μ m.
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BMP6 treated (p = 0.022) and untreated C3A cells (p = 0.016) (Fig. 4c). Levels of endofin mRNA were 
decreased which corresponds to the decrease in endofin protein levels (Fig.  4d). Consistent with the 
reduction in SMAD1/5/8 phosphorylation, in the same cells, HAMP, ID1 and SMAD7 mRNA showed 
reduced basal and BMP-induced levels following endofin knockdown (Fig. 4e–g).
Polymorphisms in the FYVE domain affects proper endofin localisation. As decreased endo-
fin expression modulated hepcidin levels, which in turn would result in increased body iron levels, we 
reasoned that single nucleotide polymorphisms (SNPs) which affected endofin localisation or function 
might have a similar effect. We identified naturally occurring endofin SNP variants through SNP database 
searches and analysed using the SIFT (Sorting Intolerant From Tolerant) and PolyPhen-2 (Polymorphism 
Figure 4. Endofin silencing reduces phosphorylation of SMAD1/5/8 proteins. C3A cells were transfected 
with non-specific siRNA (si-NS) or endofin-specific siRNA (si-Endofin) for 72 hr before treating with 
BMP6 (10 ng/ml) for 4 hr. (a) Cells were harvested and lysates were immunoblotted with antibodies against 
endofin, phospho-SMAD1/5/8. β -actin was used as a loading control. Bands developed on film were scanned 
and densitometry was used to quantify the levels of endofin (b) and pSMAD1/5/8 proteins (c) relative to 
actin using the GeneGenius Imaging System. The mRNA expression of (d) ZFYVE (Endofin), (e) HAMP, 
(f) ID1 and (g) SMAD7 were measured by qPCR and normalised to the geometric means of the reference 
genes ACTB and HPRT. Data are representative of three independent biological experiments. Bars represent 
means ± standard errors of triplicates. P-values of endofin knockdown relative to si-NS controls were 
calculated using 2-way ANOVA; *indicates a p-value of < 0.05, **p < 0.01, ***p < 0.001.
www.nature.com/scientificreports/
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Phenotyping v2) protein prediction tools to determine potentially deleterious mutations and generated 
them through site-directed mutagenesis of HA-epitope tagged endofin constructs. These were transiently 
transfected into C3A cells (Fig. 5a,b).
Intracellular endofin expression was analysed by immunofluorescence and confocal microscopy 
to determine the consequences of SNPs on endofin localisation. We observed endogenous endofin as 
vesicle-like structures in the cytoplasm that resembled endosomes. Co-localisation studies with an endo-
somal marker, early endosome antigen 1 (EEA1), showed a degree of overlap (Fig.  5c). Transfection 
with wild-type HA-epitope tagged endofin constructs showed similar localisation patterns with some 
vesicles noted to be slightly enlarged as compared to endogenous endofin. Analysis of three endofin var-
iants (E1431Q, T1519N and T928Yfs*8) all possessing an intact FYVE domain showed endosomal-like 
localisation patterns, similar to wild-type constructs. However, one non-synonymous (R766G) and two 
Figure 5. Mutations disrupting the conserved FYVE domain of endofin cause mislocalisation. Plasmid 
constructs containing six naturally occurring endofin SNPs identified to be potentially deleterious were 
generated through site-directed mutagenesis and transfected into C3A cells. After 48 hours, cells were 
immunostained with anti-HA antibodies (first column). Cells were also immunostained with organelle 
markers, EEA1 and ERp57 as represented in the second column. The nuclei were stained with DAPI as 
represented in the third column which is an overlay of the first and second panels. (a) Schematic diagram of 
endofin protein structure with the FYVE domain (red rectangle), and mapped non-synonymous (boxes) and 
frameshift (triangles) mutations. (b) Western blotting showing the corresponding sizes of proteins containing 
non-synonymous and frameshift SNPs with premature stop codons. (c) Panels show C3A cells transfected 
with endofin SNP variants without an affected FYVE domain. (d) Panels show C3A cells transfected 
with SNP variants affecting the FYVE domain. Data are representative of three independent biological 
experiments. Scale bar represents 20 μ m.
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frameshift mutations (K325Qfs*4 and N729Kfs*19) with disrupted FYVE domain regions showed a dif-
fused cytoplasmic localisation pattern. Co-localisation with the ER marker, ERp57, showed a degree of 
overlap (Fig. 5d). A similar ER localisation was also observed with the HA-tagged endofin-C753S mutant 
that also has a disrupted FYVE domain and has been shown previously to lead to incorrect localisation 
of the protein14,24.
Discussion
Previous studies have shown that endofin enhances BMP-SMAD signalling by anchoring SMAD proteins 
to BMP receptors. Here we have identified endofin as a novel signalling component required for hepcidin 
regulation, by mediating SMAD1/5/8 phosphorylation in the BMP-SMAD pathway. We also show that 
variants which affect endofin localisation may have an effect on hepcidin expression and could poten-
tially play roles as genetic modifiers of iron overload.
Knockdown of endofin with specific siRNA results in down-regulation of basal hepcidin expression. 
Knockdown of endofin also leads to a down-regulation of BMP-regulated genes, ID1 and SMAD7, indi-
cating that endofin is essential for the basal expression of genes in the BMP-SMAD pathway. Our results 
support a previous study where a mutant and non-functional form of endofin, the FYVE (C753S) mutant, 
transfected in mouse myoblast C2C12 cells was found to decrease expression of a BMP-responsive reporter 
gene13. Conversely, stable constructs of the wild-type form slightly enhanced reporter gene expression.
Several BMPs have been shown to induce hepcidin expression in vitro25–27. Only BMP6 was found 
to be an essential and non-redundant regulator of hepcidin and iron in vivo25. To determine if endofin 
regulates BMP-induced hepcidin expression, we silenced endofin and examined hepcidin expression in 
BMP6-treated C3A cells. Despite 100-fold induction of hepcidin with BMP6, we observed an inhibition 
of hepcidin expression compared to controls suggesting that endofin is important for the BMP regula-
tion of hepcidin. The importance of endofin in modulating BMP signals was previously shown in vivo 
in Xenopus embryos, where endofin regulated BMP-induced mesodermal patterning, as characterised 
by increased expression of early mesodermal markers Xbra, Xhox3 and Xwnt8. Expression of the FYVE 
(C753S) mutant showed decreased expression of mesodermal markers despite stimulation with BMPs 
indicating that endofin is required for BMP signalling13.
SMAD anchors are known to mediate TGFβ signalling by interacting and localising SMAD proteins 
to TGFβ receptors. However, recent findings through co-immunoprecipitation (co-IP) show that they are 
dispensable for the pathway28,29. For the first time, we demonstrate an in situ interaction of endofin and 
SARA with SMAD1 and SMAD2/3, respectively. This validates previous reports on the role of SMAD 
anchors in mediating TGFβ signalling12,13,30,31. In addition, we found that endofin interacted similarly to 
SMAD2/3 suggesting a possible role of endofin in both the BMP and TGFβ signalling pathways. This 
was previously shown in the human embryonic kidney cell line, HEK293T, and other human hepatic 
cell lines, Hep3B and HepG232.
To determine the underlying mechanism of hepcidin regulation by endofin, we examined the effects 
of endofin silencing on SMAD activation. SMAD1/5/8 proteins are receptor-regulated SMADs that trans-
duce BMP signals from membrane receptors to the nucleus and activate the expression of BMP-responsive 
genes. We observed that the knockdown of endofin caused a decrease in SMAD1/5/8 phosphorylation 
in both BMP6-treated and untreated control cells. Measurement of relative hepcidin mRNA expres-
sion correspondingly showed a down-regulation following endofin knockdown suggesting that endo-
fin mediates SMAD1/5/8 phosphorylation which subsequently influences hepcidin expression. This is 
similar to previous findings where endofin facilitates expression of BMP-regulated genes through its 
interaction with different SMADs. Endofin was shown to enhance BMP-SMAD signalling by interacting 
with unphosphorylated SMAD1 and anchoring SMAD1 to BMP receptors for activation13. Endofin also 
enhances BMP-SMAD signalling by interacting with SMAD4, recruiting SMAD4 to activated SMADs 
to mediate SMAD complex formation32. These SMAD complexes then shuttle to the nucleus to induce 
transcription of targeted genes.
Deleterious mutations in genes encoding hepcidin or its regulators result in dysregulated production 
of hepcidin and cause genetic disorders of iron homeostasis. As endofin was able to modulate hepci-
din expression, we carried out further studies to determine if endofin was a potential genetic modi-
fier of iron-related disorders. Endofin variants from SNP databases such as HAPMAP, 1000 Genomes 
Project and NCBI dbSNP were analysed using protein prediction tools; we identified six variants that 
were potentially deleterious. Characterisation via indirect immunofluorescence showed that the FYVE 
domain of endofin was important for its localisation to endosomes. Endofin SNP variants with an intact 
FYVE domain showed endosomal localisation patterns similar to the wild-type and endogenous end-
ofin protein. However, variants containing a premature stop codon or a non-synonymous mutation in 
the conserved FYVE domain showed a diffused localisation pattern resembling the ER. Localisation of 
these FYVE domain variants were consistent with a previously reported synthetic mutant FYVE (C753S) 
that also disrupts the FYVE domain14. As the FYVE domain is essential in recruiting SMADs to early 
endocytic compartments, it could potentially affect the SMAD trafficking function of endofin and dis-
rupt hepcidin transcription15. Previous findings have associated a disrupted FYVE domain with delay in 
membrane trafficking, reduced SMAD activity and attenuation of BMP signalling13,14,32. It is thus possible 
that endofin may act as a genetic modifier in iron-related disorders such as iron overload caused by 
HFE C282Y, where phenotypic variance is displayed despite homozygous mutations. As such, it would 
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be of interest to assess in vivo effects of naturally occurring endofin SNPs with other genetic mutations 
that cause iron-related disorders. A SNP in endofin has been previously associated with susceptibility 
to psoriasis, a disease where TGFβ and SMAD signalling have been implicated33,34. However, endofin 
SNPs have not been observed in genome wide association studies that have investigated alterations in 
iron parameters35,36.
Since endofin is involved in endosomal trafficking, it remains unclear if endofin specifically mod-
ulates the BMP-SMAD signalling pathway. Endofin is described in previous studies to be associated 
with other signalling pathways such as the mitogen-activated protein kinase (MAPK) pathway and the 
closely-related TGFβ -SMAD signalling pathway24,32. Endofin is a tyrosine target of EGF signalling in 
A431 cells37. Expression of endofin constructs with a mutated Y515 tyrosine phosphorylation site in 
HeLa cells enhanced ERK2 phosphorylation, suggesting that endofin plays a role in modulating the 
MAPK/ERK signalling pathway24. In another study, endofin was shown to affect the TGFβ -SMAD sig-
nalling pathway by interacting with TGFβ type I receptors32. Furthermore, the knockdown of endofin in 
Hep3B cells attenuated SMAD2-responsive gene expression32. However, the study also reported that the 
influence of endofin on TGFβ -SMAD signalling was specific and did not affect BMP or Wnt signalling. 
Future work involves further characterising the specific signalling pathways regulated by endofin.
In conclusion, we have identified endofin as an important signalling component required for basal and 
BMP-induced hepcidin expression. Endofin influences hepcidin expression by regulating SMAD1/5/8 
phosphorylation which is central for the transcription of hepcidin (Fig. 6). Identification of the hitherto 
unrecognised role of endofin further elucidates the molecular network involved in hepcidin regulation 
which may aid in the management of iron-related disorders.
Materials and Methods
Cell Culture. HepG2/C3A hepatoma cells (cat. no. CRL-10741, ATCC, Manassas, VA, USA) were 
maintained in Minimum Essential Medium (MEM) containing 10% FCS.
Transfection with DNA and small interfering RNA (siRNA) constructs. DNA transfection. 
C3A cells were grown in 12-well cluster plates (~4 cm2) to 80–90% confluence before transfection. 
pDHA-Neo-Endofin plasmids, described previously14, were transfected using Lipofectamine 3000 (Life 
Technologies, Mulgrave, Australia) according to the manufacturer’s recommendations. Cells were incu-
bated with the DNA-Lipofectamine complexes (100 μ l per well) for 48 hours.
siRNA transfection. C3A cells were counted and grown to 30–40% confluence in 12-well clus-
ter plates (~4 cm2) before transfection with 20 pmol of non-specific or endofin siRNA (GenePharma, 
Shanghai, China) in complex with Lipofectamine RNAiMAX (Life Technologies). Sequences of the siR-
NAs used were as follows: non-specific (si-NS) forward 5′ -UUCUCCGAACGUGUCACGUTT-3′ and 
Figure 6. Schematic diagram of hepcidin regulation by endofin through the BMP-SMAD pathway. 
Upon BMP ligand binding, Type II Receptors phosphorylate Type I Receptors at the glycine-serine domain 
resulting in its activation, and phosphorylation of the R-SMADs, SMAD1/5/8, which subsequently form 
heterocomplexes with SMAD4 before translocating to the nucleus to activate the transcription of hepcidin. 
Endofin, which recruits SMADs to BMP receptors, mediates SMAD1/5/8 phosphorylation and consequently 
regulates hepcidin expression.
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reverse 5′ -ACGUGACACGUUCGGAGAATT-3′ , endofin (si-Endofin) forward 5′ -GGGCAAGACUU 
AGAUUACUTT-3′ and reverse 5′ -AGUAAUCUAAGUCUUGCCCTT-3′ . Briefly, the siRNAs were 
diluted in 50 μ l Opti-MEM and mixed gently. Subsequently, 2 μ l of Lipofectamine RNAiMAX was diluted 
in 50 μ l Opti-MEM and mixed gently. The siRNA-Lipofectamine complexes were mixed gently and incu-
bated at room temperature for 5–10 min. The complex (100 μ l) was subsequently added to each well of 
cells and incubated for 72 hours before harvesting.
Real-Time PCR analysis of mRNA transcripts. Total RNA was isolated from cells using Trizol 
reagent (Life Technologies) according to the manufacturer’s recommendations. RNA (1 μ g) was reverse 
transcribed into cDNA using Superscript III (Life Technologies). Reactions were performed on the Viia7 
Real Time PCR System (Life Technologies) as described previously38. Primer pairs for detecting mRNA 
transcripts are described in Table  1. All targets were normalised to the geometric means of reference 
genes, ACTB and HPRT using 2−ΔCT.
Proximity Ligation Assays (PLA). The mouse/rabbit red starter Duolink kit (Sigma-Aldrich) was 
used for this experiment. HepG2/C3A cells were seeded at 10 × 104 cells per well in a 12-well cluster 
plate and transfected with pDMyc-Neo-Endofin14 or pDMyc-Neo-SARA14 plasmids as described above. 
The cells were fixed and permeabilised as described previously39. After permeabilisation the cells were 
incubated in the blocking buffer (provided with the kit) for 1 hr at 37 °C in a humidified chamber. Next, 
cells were incubated with the primary antibodies diluted in the antibody diluents for 1 hr at room tem-
perature. Primary antibodies used were mouse anti-Myc 9B11 (1:2000; Cell Signaling Technology), rabbit 
anti-SMAD1 (1:50; Life Technologies), rabbit anti-SMAD2/3 (1:800; Cell Signaling Technology), mouse 
anti-TfR1 (1:500; Life Technologies) and rabbit anti-TfR1 (1:100; Abcam, Cambridge, UK). Cells were 
then washed in Buffer A (supplied with the kit) 2 times for 5 min each and incubated with the PLA 
probes for one hour at 37 °C in a humidified chamber. Cells were washed 2 times for 5 min each in Buffer 
A before the ligation step at 37 °C for one hour in a humid chamber. Following 2 times of 2 min washes, 
cells were incubated with the amplification mix for 2 hr at 37 °C in a darkened humidified chamber. Cells 
were washed with 1 × Buffer B (supplied with the kit) 2 times for 10 minutes followed by a 1 min wash 
with 0.01 × Buffer B before mounting on cover slips using the mounting media supplied with the kit.
Western blotting. Cell lysates were homogenised in phosphatase inhibitor lysis buffer and western 
blotting was carried out as previously described40. Blots were incubated with antibodies: anti-endofin14 
(1:30000), anti-phospho-SMAD1/5/8 (1:3000; Cell Signaling Technology, Danvers MA, USA), 
anti-HA 12CA5 hybridoma supernatant (1:2000; ATCC, Manassas, VA, USA) and anti-actin (1:20000; 
Sigma-Aldrich, Missouri, USA). Bands developed on film were scanned using Scanmaker 9800 XL plus 
(Microtek International Inc. Hsinchu, Taiwan) and subsequently quantified by densitometry using the 
GeneGenius Imaging System (Syngene, Cambridge, UK).
Mutagenesis. Endofin variants were identified through SNP database searches (http://www.ncbi.
nlm.nih.gov/projects/SNP) and were analysed using Sorting Intolerant From Tolerant (SIFT; http://
sift.jcvi.org/) and Polymorphism Phenotyping v2 (PolyPhen-2; http://genetics.bwh.harvard.edu/pph2/) 
programs. Six variants (rs13157990, rs61741923, rs16877836, rs35915800, rs34397330 and rs35033083) 
Gene Primer Sequence
ACTB (β-ACTIN)
F CAGGCACCAGGGCGTG
R GCCCACATAGGAATCCTTCTGA
HPRT1
F GAAAGGGTGTTTATTCCTCAT
R CCCATCTCCTTCATCACAT
HAMP (Hepcidin)
F CCACAACAGACGGGACAAC
R AAAATGCAGATGGGGAAGTG
ID1
F TGGAGCTGAACTCGGAATCCG
R GACACAAGATGCGATCGTCCG
SMAD7
F TCACCTTAGCCGACTCTGCG
R GTTTCAGCGGAGGAAGGCAC
ZFYVE9 (SARA)
F CTGTGCTTCCTGCTGTAGCCTGAAA
R TTAGGGCTCTGGCTTGAGGCACT
ZFYVE16 (Endofin)
F ATGGCTTGTAGTGCTGCGCTGT
R AGGCAGAAGTTGGCCTTCAGATCC
Table 1.  Sequence of primer pairs used for qPCR.
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with potentially deleterious mutations, as predicted by these programs, were selected for mutagene-
sis. All primers designed to introduce the site-directed mutation were synthesised by Integrated DNA 
Technologies (IDT, Coralville, Iowa). Mutations were introduced into HA-tagged endofin constructs in 
pDHA14 with the primers listed in Table 2. Mutagenesis was then carried out according to Scott et al.41 
with changes as noted: a PCR mixture containing 75 ng template plasmid DNA, 2 μ M of each oligonucle-
otide, 2 mM dNTPs, 50 U KOD DNA polymerase (Merck Chemicals, Victoria, Australia) and polymerase 
buffer in a total volume of 50 μ l. PCR was performed under the following conditions; denaturation at 
95 °C for 2 min, followed by 18 cycles of denaturation at 95 °C for 20 seconds, annealing at 58 °C for 
10 seconds and extension at 68 °C for 5 minutes. The endofin insert was sequenced to ensure that the 
generated mutation was present and no other unintentional sequence changes had been inserted during 
the mutagenesis procedure.
Indirect immunofluorescence microscopy. Cultured cells were grown on glass coverslips over-
night and were prepared for immunofluorescence as described previously42. Primary antibodies used 
to assess expression were rabbit anti-endofin14 (1:500), rabbit anti-HA H6908 (1:100; Sigma-Aldrich), 
mouse anti-EEA1 (1:400; BD Transduction Labs, San Jose, CA, USA) and rabbit anti-ERp5743 (1:600; 
a gift from Prof. Stephen High, University of Manchester, Manchester, UK). Cells were mounted onto 
glass slides using ProLong Gold anti-fade with 4′ , 6-diamidino-2-phenylindole dihydrochloride (DAPI) 
(Molecular Probes, Life Technologies, Mulgrave, Australia). Fluorescent images were viewed and cap-
tured using a Zeiss LSM 780 NLO inverted confocal microscope (Carl Zeiss, Oberkochen, Germany).
Statistical analysis. Statistics were generated using GraphPad Prism software v.6.0 (GraphPad 
Software, San Diego CA, USA). Results were expressed as the mean ± standard error. Variables were 
compared between groups using two way analysis of variance (2-way ANOVA). Post-hoc analysis was 
performed to compare the differences between groups using Tukey’s multiple comparison test. Statistical 
significance is indicated as follows: *indicates a p-value of < 0.05, **p < 0.01, ***p < 0.001. Graphs were 
prepared using Graphpad Prism 6.
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